Detectable C-Peptide and Diabetic Ketoacidosis Risk in Type 1 Diabetes
Diabetes Care · 2026
DOI: 10.2337/dc26-0220 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Diabetes Care, 2026. Verfasst von Mohammad I Abuabat und 12 weiteren Autor:innen. Beteiligte Einrichtung: Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: C-Peptide, Diabetic Ketoacidosis, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE To investigate whether detectable C-peptide levels in type 1 diabetes is associated with a lower risk of diabetic ketoacidosis (DKA). RESEARCH DESIGN AND METHODS We analyzed the Diabetes Control and Complications Trial publicly available data repository for the association between detectable stimulated C-peptide (>0.2 nmol/mL, measured annually) and DKA incidence over an average 6.5-year follow-up. We used crude and adjusted Andersen-Gill models for recurrent DKA events with time-dependent covariates. RESULTS Of the 1,441 participants (53% male, median age 27 years), 129 (9%) experienced 180 DKA events. Of these events, 179 (99.44%) occurred after C-peptide was ≤0.2 nmol/L in the prior year and only 1 event occurred with C-peptide >0.2 nmol/L. C-peptide >0.2 nmol/L was associated with a DKA hazard ratio of 0.07 (95% CI 0.01–0.48; P = 0.007), consistent across adjusted models. CONCLUSIONS Endogenous insulin production was significantly associated with lower DKA risk, suggesting that treatments preserving insulin production could decrease long-term DKA risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
- Division of Endocrinology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Internal Medicine and Critical Care Department, King Abdullah bin Abdulaziz University Hospital, Princess Norah University, Riyadh, Saudi Arabia.
- Division of General Internal Medicine, Department of Medicine, University Health Network and Sinai Health, University of Toronto, Toronto, Ontario, Canada.
- Kidney and Pancreas Health Centre, Organ Transplant Centre of Excellence, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
- Patient-partner (person with lived type 1 diabetes experience).
ORCID-Profile: Yucheng Zhang, Bruce A Perkins
Zitieren
APA
Abuabat, M. I., Budhram, D., Bapat, P., Bakhsh, A., Zhang, Y., Cheema, W., Verhoeff, N. J., Mumford, D., Orszag, A., Fralick, M., Weisman, A., Lovblom, L. E., & Perkins, B. A. (2026). Detectable C-Peptide and Diabetic Ketoacidosis Risk in Type 1 Diabetes. Diabetes Care. https://doi.org/10.2337/dc26-0220
Vancouver
Abuabat MI, Budhram D, Bapat P, Bakhsh A, Zhang Y, Cheema W, et al. Detectable C-Peptide and Diabetic Ketoacidosis Risk in Type 1 Diabetes. Diabetes Care. 2026. doi:10.2337/dc26-0220
BibTeX
@article{Abuabat2026,
author = {Abuabat, Mohammad I and Budhram, Dalton and Bapat, Priya and Bakhsh, Abdulmohsen and Zhang, Yucheng and Cheema, Wajeeha and Verhoeff, Natasha J and Mumford, Doug and Orszag, Andrej and Fralick, Michael and Weisman, Alanna and Lovblom, Leif Erik and Perkins, Bruce A},
title = {Detectable C-Peptide and Diabetic Ketoacidosis Risk in Type 1 Diabetes},
journal = {Diabetes Care},
year = {2026},
doi = {10.2337/dc26-0220}
}
EUVIMED